Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 6/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638898 | 0.93 | MAPK14 (0.58) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6638914 | 0.93 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6642607 | 0.90 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6640798 | 0.88 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6642435 | 0.87 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6638395 | 0.86 | MAPK14 (0.58) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6639248 | 0.86 | MAPK14 (0.56) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6641557 | 0.85 | MAPK13 (0.56) | MAPK13MAPK12MAPK11MAPK14CTSS | |
| SCHEMBL6640277 | 0.85 | MAPK14 (0.65) | MAPK13MAPK12MAPK11MAPK14SCN9A | |
| SCHEMBL6639546 | 0.85 | MAPK14 (0.65) | MAPK13MAPK12MAPK11MAPK14SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948495-B1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | claimed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | claimed |
| EP-0948495-B1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6605634-B2 | Tumor necrosis factor alpha and interleukin-1 (IL-1) mediated diseases; pain, diabetes; cyclooxygenase inhibition | AMGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | TNF, IL1A, IL6 | MAPK13 2534/4885MAPK12 1983/4885MAPK11 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.